Institution
Paris Descartes University
Government•Paris, France•
About: Paris Descartes University is a government organization based out in Paris, France. It is known for research contribution in the topics: Population & Transplantation. The organization has 20987 authors who have published 37456 publications receiving 1206222 citations. The organization is also known as: Université Paris V-Descartes & Université de Paris V.
Topics: Population, Transplantation, Immune system, Cancer, Pregnancy
Papers published on a yearly basis
Papers
More filters
TL;DR: The four most commonly used spherical cancer models in cancer research are proposed based on culture methods for obtaining them and on subsequent differences in sphere biology: the multicellular tumor spheroid model, first described in the early 70s and obtained by culture of cancer cell lines under nonadherent conditions; tumorospheres, a model of cancer stem cell expansion established in a serum-free medium supplemented with growth factors.
861 citations
TL;DR: In this paper, the authors present a review of the state of the art in the field of anaesthesia and intensive care medicine at the University of Oslo and the Norwegian Department of Anesthesia and Intensive Care Medicine at the Norwegian National Institute of Emergencies and Critical Care.
849 citations
Université Paris-Saclay1, University of Toronto2, Karolinska University Hospital3, Pierre-and-Marie-Curie University4, Cincinnati Children's Hospital Medical Center5, Memorial Sloan Kettering Cancer Center6, Necker-Enfants Malades Hospital7, Paris Descartes University8, University of Texas MD Anderson Cancer Center9, Icahn School of Medicine at Mount Sinai10, University of Pittsburgh11, Harvard University12, Brigham and Women's Hospital13, Mayo Clinic14
TL;DR: This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocyts and macrophage activation syndrome.
848 citations
Carlos III Health Institute1, University of Cologne2, University of Sydney3, Paris Descartes University4, Universidade Federal de Ciências da Saúde de Porto Alegre5, Pontifícia Universidade Católica do Rio Grande do Sul6, University of California, San Diego7, Medical University of Graz8, University of Copenhagen9, Katholieke Universiteit Leuven10, University of Bologna11, University of the Witwatersrand12, RMIT University13, McGill University14, Hacettepe University15, University of Paris16, Utrecht University17, Mazandaran University of Medical Sciences18, Tel Aviv University19, Hospital General de México20, Istituto Giannina Gaslini21, Mahidol University22, Federal University of São Paulo23, King's College, Aberdeen24, Comenius University in Bratislava25, Boston Children's Hospital26, Hospital General Universitario Gregorio Marañón27, Complutense University of Madrid28, University Hospital Heidelberg29, University of California, Los Angeles30, American University of Beirut31, Innsbruck Medical University32, University of Lausanne33, Catholic University of Korea34, Goethe University Frankfurt35, National and Kapodistrian University of Athens36, Erasmus University Rotterdam37, Monash University38, Federal University of Rio de Janeiro39, Catholic University of the Sacred Heart40, University of Health Sciences Antigua41, National Institutes of Health42, Amrita Institute of Medical Sciences and Research Centre43, University of Pittsburgh44, University of Melbourne45, Peter MacCallum Cancer Centre46, P. D. Hinduja Hospital and Medical Research Centre47, University of Southern California48, Duke University49, Singapore General Hospital50, NewYork–Presbyterian Hospital51, Cardiff University52, University of Texas Health Science Center at San Antonio53, Children's Hospital of Philadelphia54, Post Graduate Institute of Medical Education and Research55
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Abstract: Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.
842 citations
University of Bologna1, The Royal Marsden NHS Foundation Trust2, Goethe University Frankfurt3, Paris Descartes University4, University of Bergen5, Innsbruck Medical University6, University of Pavia7, Policlinico Umberto I8, University of Verona9, École Normale Supérieure10, Haukeland University Hospital11, University of Medicine and Pharmacy of Craiova12
TL;DR: The clinical part of these Guidelines and Recommendations produced under the auspices of the European Federation of Societies for Ultrasound in Medicine and Biology EFSUMB assesses the clinically used applications of all forms of elastography, stressing the evidence from meta-analyses and giving practical advice for their uses and interpretation.
Abstract: The clinical part of these Guidelines and Recommendations produced under the auspices of the European Federation of Societies for Ultrasound in Medicine and Biology EFSUMB assesses the clinically used applications of all forms of elastography, stressing the evidence from meta-analyses and giving practical advice for their uses and interpretation. Diffuse liver disease forms the largest section, reflecting the wide experience with transient and shear wave elastography . Then follow the breast, thyroid, gastro-intestinal tract, endoscopic elastography, the prostate and the musculo-skeletal system using strain and shear wave elastography as appropriate. The document is intended to form a reference and to guide clinical users in a practical way.
830 citations
Authors
Showing all 21023 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Guido Kroemer | 236 | 1404 | 246571 |
| Cyrus Cooper | 204 | 1869 | 206782 |
| Jean-Laurent Casanova | 144 | 842 | 76173 |
| Alain Fischer | 143 | 770 | 81680 |
| Maxime Dougados | 134 | 1054 | 69979 |
| Carlos López-Otín | 126 | 494 | 83933 |
| Giuseppe Viale | 123 | 740 | 72799 |
| Thierry Poynard | 119 | 668 | 64548 |
| Lorenzo Galluzzi | 118 | 477 | 71436 |
| Shahrokh F. Shariat | 118 | 1637 | 58900 |
| Richard E. Tremblay | 116 | 685 | 45844 |
| Olivier Hermine | 111 | 1026 | 43779 |
| Yehezkel Ben-Ari | 110 | 459 | 44293 |
| Loïc Guillevin | 108 | 800 | 51085 |
| Gérard Socié | 107 | 920 | 44186 |